Senior Counsels Jason Drori and Simon Elliott contributed an article to IPPro Patents
, “The PRICED Act: A Bold Attempt to Change the Biologics Market
,” on August 17, 2016. The article examined the Price Relief, Innovation, and Competition for Essential Drugs (PRICED) Act proposed legislation that aims to reduce the market exclusivity period for new biologics from 12 to seven years in the United States. Drori and Elliott discussed how the PRICED Act may be a more direct threat to the biologics industry and risks upsetting a delicate balance.